This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 105/1/12    most recent CIRCRESAHA.109.198416v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Koitabashi, N. Articles by Kass, D. A. PubMed PubMed Citation Articles by Koitabashi, N. Articles by Kass, D. A. Related Collections Contractile function Cardiovascular Pharmacology Gene expression Genetically altered mice Heart failure - basic studies

(Circulation Research. 2009;105:12.)
© 2009 American Heart Association, Inc.

Report

Avoidance of Transient Cardiomyopathy in Cardiomyocyte-Targeted Tamoxifen-Induced MerCreMer Gene Deletion Models

Norimichi Koitabashi, Djahida Bedja, Ari L. Zaiman, Yigal M. Pinto, Manling Zhang, Kathleen L. Gabrielson, Eiki Takimoto, David A. Kass

From the Divisions of Cardiology (N.K., M.Z., E.T., D.A.K.) and Pulmonary and Critical Care Medicine (A.L.Z.), Department of Medicine; and Division of Comparative Medicine (D.B., K.L.G.), Johns Hopkins Medical Institutions, Baltimore, Md; and University of Amsterdam (Y.M.P.), Heart Failure Research Center, The Netherlands.

Correspondence to: David A. Kass, MD, Division of Cardiology, Johns Hopkins Medical Institutions, Ross Research Building, Room 858, 720 Rutland Ave, Baltimore, MD 21205. E-mail dkass{at}jhmi.edu

Cardiac myocyte targeted MerCreMer transgenic mice expressing tamoxifen-inducible Cre driven by the -myosin heavy chain promoter are increasingly used to control gene expression in the adult heart. Here, we show tamoxifen-mediated MerCreMer (MCM) nuclear translocation can induce severe transient dilated cardiomyopathy in mice with or without loxP transgenes. The cardiomyopathy is accompanied by marked reduction of energy/metabolism and calcium-handling gene expression (eg, PGC1-, peroxisome proliferator-activated , SERCA2A), all fully normalized with recovery. MCM-negative/flox-positive controls display no dysfunction with tamoxifen. Nuclear Cre translocation and equally effective gene knockdown without cardiomyopathy is achievable with raloxifene, suggesting toxicity is not simply from Cre. Careful attention to controls, reduced tamoxifen dosing and/or use of raloxifene is advised with this model.

Key Words: inducible transgenic • Cre recombinase • selective estrogen receptor modulator • ventricular function • mouse models